Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ficlatuzumab,Cetuximab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Aveo Oncology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
AVEO Oncology Regains Full Global Rights to Ficlatuzumab
Details : Under the terms of the deal, Biodesix will continue to fund 50% of the ongoing HNSCC Phase 2 trial of ficlatuzumab, and will be entitled to a low double digit royalty on any future product sales as well as 25% of future licensing revenue, subject to cert...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
August 09, 2020
Lead Product(s) : Ficlatuzumab,Cetuximab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Aveo Oncology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ficlatuzumab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : AVEO Pharmaceuticals, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 24, 2019
Lead Product(s) : Ficlatuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : AVEO Pharmaceuticals, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ficlatuzumab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : AVEO Pharmaceuticals, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
December 17, 2014
Lead Product(s) : Ficlatuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : AVEO Pharmaceuticals, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 30, 2012
Reset All
